登录 | 注册
牛蒡根茯苓方纳米制剂对马兜铃酸所致肾损伤的保护作用研究
Study on the protective effect of Burdock Root and Poria Cocos Nano-formulations against Aristolochic acid-induced renal injury
ES评分 0 浏览量:61 下载量:0
1 北京煦堂生物科技有限公司 北京 2 纳米技术及应用国家工程研究中心 上海 3 上海交通大学 上海
[1] Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A review [J]. JAMA, 2019, 322(13): 1294-1304.
[2] Wang F, Yang C, Long J, et al. Executive summary for the 2015 annual data report of the china kidney disease network (ck-net) [J]. Kidney Int, 2019, 95(3): 501-505.
[3] Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the global burden of disease study 2019 [J]. Lancet, 2020, 396(10258): 1204-1222.
[4] Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease [J]. Adv Exp Med Biol, 2019, 1165: 3-15.
[5] 姬满山, 周竹. 慢性肾脏病的中西医治疗进展 [J]. 云南医药, 2025, 46(05): 86-89.
[6] 黄露艳. 肾损伤的中医认识与治疗 [J]. 四川中医, 2020, 38(04): 44-47.
[7] Teja PK, Mithiya J, Kate AS, et al. Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview [J]. Phytomedicine, 2022, 96: 153890.
[8] Liu M, Chen X, Chen H, et al. Nanotechnology-based drug delivery system for anticancer active ingredients from traditional chinese medicines: A review [J]. Am J Chin Med, 2022, 50(8): 2011-2032.
[9] Zhang YB, Wang JF, Wang MX, et al. Nano-based drug delivery systems for active ingredients from traditional chinese medicine: Harnessing the power of nanotechnology [J]. Front Pharmacol, 2024, 15: 1405252.
[10] 何语涵, 李育霈, 苏白海. 纳米药物治疗慢性肾脏病的研究进展 [J]. 临床肾脏病杂志, 2025, 25(06): 516-520.
[11] Huang Y, Ning X, Ahrari S, et al. Physiological principles underlying the kidney targeting of renal nanomedicines [J]. Nat Rev Nephrol, 2024, 20(6): 354-370.
[12] Cosyns JP. Aristolochic acid and 'chinese herbs nephropathy': A review of the evidence to date [J]. Drug Saf, 2003, 26(1): 33-48.
[13] 孙梦豫, 邓清月, 孙澜彬, 等. 数据挖掘《中国药典》2020年版肾病相关中药成方制剂的核心药对及其作用靶点预测 [J]. 中草药, 2025, 56(01): 191-202.
[14] Yosri N, Alsharif SM, Xiao J, et al. Arctium lappa (burdock): Insights from ethnopharmacology potential, chemical constituents, clinical studies, pharmacological utility and nanomedicine [J]. Biomed Pharmacother, 2023, 158: 114104.
[15] Nie A, Chao Y, Zhang X, et al. Phytochemistry and pharmacological activities of wolfiporia cocos (f.A. Wolf) ryvarden & gilb [J]. Front Pharmacol, 2020, 11: 505249.
[16] Feng YL, Cao G, Chen DQ, et al. Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease [J]. Cell Mol Life Sci, 2019, 76(24): 4961-4978.
[17] Zhang J, Wu C, Gao L, et al. Astragaloside iv derived from astragalus membranaceus: A research review on the pharmacological effects [J]. Adv Pharmacol, 2020, 87: 89-112.
[18] 吕冬菊, 黄东明, 段伟静. 黄芪甲苷调控hmgb1/nf-κb通路对脓毒症大鼠巨噬细胞极化和急性肾损伤的机制研究 [J]. 中国煤炭工业医学杂志, 2025, 28(01): 1-7.
[19] 孙健, 樊卫平, 郎捷. 黄芪总皂苷对免疫球蛋白 a 肾病大鼠肾损伤的保护作用及其对 tgf-β/smad 信号通路的影响研究 [J]. 中华中医药学刊: 1-13.
[20] Rios JL. Chemical constituents and pharmacological properties of poria cocos [J]. Planta Med, 2011, 77(7): 681-691.
[21] Suryantoro SD, Iwanoski G, Sutanto H, et al. Resveratrol in renal health: Bridging therapeutic gaps from acute kidney injury to chronic disease prevention [J]. J Physiol, 2024, 602(10): 2165-2167.
彭家伟, 史小方, 宋存峰, 周宁, 朱翔. 牛蒡根茯苓方纳米制剂对马兜铃酸所致肾损伤的保护作用研究 [J]. 国际中医药研究. 2025; 5; (4). 17 - 22.
Copyright © 2023 CSCIED科技核心评价数据库 版权所有 京ICP备
Email:info@cscied.com网址:www.cscied.com
互联网出版许可证违法和不良信息举报中心举报邮箱:jubao@cscied.com